Quoin Pharmaceuticals, Ltd.(QNRX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
QNRX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Quoin Pharmaceuticals, Ltd. (QNRX), a Healthcare sector company. QNRX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Quoin Pharmaceuticals, Ltd. reports net income of $-5.0M, free cash flow of $-4.9M. Top institutional holders of QNRX by reported 13-F value include Ikarian Capital,, Dauntless Investment Group,, SummitTX Capital, L.P., based on the most recent SEC filings. QNRX trades on the Nasdaq exchange and files with the SEC under CIK 1671502. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate QNRX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Quoin Pharmaceuticals, Ltd. directly from SEC EDGAR.
Net Income
Q1 2026
$-5.0M
Free Cash Flow
Q1 2026
$-4.9M
AI Insight: QNRX Financial Trends
Quoin is a pre-revenue clinical-stage burner: net losses doubled to -$5M and equity turned negative in Q3 2025 before a capital injection temporarily lifted it to $9M.
• Net losses doubled from -$2M per quarter in Q2–Q4 2024 to -$5M in Q1 2026, signaling accelerating cash consumption.
• Operating cash outflows widened from -$2M in Q2 2024 to -$5M in both Q4 2025 and Q1 2026.
• Equity turned negative at -$1M in Q3 2025 before rebounding to $13M in Q4 2025, indicating a dilutive capital raise.
⚠ Equity fell from $13M in Q4 2025 to $9M in Q1 2026; at the current burn rate, the runway is limited.
⚠ Zero revenue across all eight quarters — any clinical or regulatory milestone triggering commercialization is the key inflection.
AI Insight: QNRX Ratio Trends
Data is too sparse to establish meaningful trends — only ROE and ROA are partially populated, revealing persistent deep losses but no directional signal.
• ROE swung from -105.6% in Q2 2024 to -172.7% in Q3 2024, then recovered to -100.4% in Q4 2024, showing high volatility.
• ROA ranged from -56.2% in Q2 2024 to -85.3% in Q4 2025, indicating consistently heavy asset losses with no improvement.
• OpMargin, NPM, ROIC, and D/E are entirely absent across all periods, leaving capital structure and profitability largely unassessable.
⚠ TTM ROE of -193.7% is the most negative in the dataset — signals accelerating equity erosion through early 2026.
⚠ Gaps in Q1–Q3 2025 ROE/ROA make it impossible to assess whether losses widened or narrowed mid-year.
Get alerted when QNRX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Quoin Pharmaceuticals, Ltd. including:
Top Institutional Holders of QNRX
Ikarian Capital, LLC
$1.4M211,538 shDauntless Investment Group, LLC
$1.3M196,592 shSummitTX Capital, L.P.
$662.0K100,300 shVelan Capital Investment Management LP
$560.0K84,849 shWoodline Partners LP
$525.2K79,582 shMILLENNIUM MANAGEMENT LLC
$503.2K76,247 shabrdn plc
$495.0K75,000 shSoleus Capital Management, L.P.
$480.0K72,730 shCentiva Capital, LP
$396.0K60,000 shBOOTHBAY FUND MANAGEMENT, LLC
$394.9K59,838 sh
| Fund | Value | Shares |
|---|---|---|
| Ikarian Capital, LLC | $1.4M | 211,538 |
| Dauntless Investment Group, LLC | $1.3M | 196,592 |
| SummitTX Capital, L.P. | $662.0K | 100,300 |
| Velan Capital Investment Management LP | $560.0K | 84,849 |
| Woodline Partners LP | $525.2K | 79,582 |
| MILLENNIUM MANAGEMENT LLC | $503.2K | 76,247 |
| abrdn plc | $495.0K | 75,000 |
| Soleus Capital Management, L.P. | $480.0K | 72,730 |
| Centiva Capital, LP | $396.0K | 60,000 |
| BOOTHBAY FUND MANAGEMENT, LLC | $394.9K | 59,838 |
More Healthcare Companies
View all Healthcare →Put QNRX on your watchlist
Track score changes the day Quoin Pharmaceuticals, Ltd. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is QNRX a good stock to buy?
13F Pro's AI-powered analysis of Quoin Pharmaceuticals, Ltd. (QNRX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for QNRX are available on the QNRX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own QNRX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling QNRX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Quoin Pharmaceuticals, Ltd.'s investment landscape.